- By insider
CEO of Beigene Ltd (BGNE) John Oyler sold 219,400 shares of BGNE on 07/06/2017 at an average price of $64.82 a share. The total sale was $14.2 million.
BeiGene Ltd is a clinical-stage biopharmaceutical company engaged in the discovery & development of molecularly targeted & immuno-oncology drugs for the treatment of cancer. Its product include BGB-3111, BGB-283 and BGB-290 and one immuno-oncology agent. BeiGene Ltd has a market cap of $2.83 billion; its shares were traded at around $70.85 with and P/S ratio of 5904.16.
-
Warning! GuruFocus has detected 3 Warning Sign with BGNE. Click here to check it out.
-
The intrinsic value of BGNE
CEO Recent Trades:
-
CEO, 10% Owner John Oyler sold 219,400 shares of BGNE stock on 07/06/2017 at the average price of $64.82. The price of the stock has increased by 9.3% since.
-
CEO, 10% Owner John Oyler sold 98,500 shares of BGNE stock on 06/23/2017 at the average price of $44.16. The price of the stock has increased by 60.44% since.
Directors and Officers Recent Trades:
-
Director Xiaodong Wang sold 35,000 shares of BGNE stock on 06/28/2017 at the average price of $44.95. The price of the stock has increased by 57.62% since.
For the complete insider trading history of BGNE, click here
.This article first appeared on GuruFocus.
-
Warning! GuruFocus has detected 3 Warning Sign with BGNE. Click here to check it out.
-
The intrinsic value of BGNE